Hansa Biopharma AB (publ) HNSA
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Hold; consider scaling in gradually on weakness into/after the H1 report and CMD, while keeping sizing constrained due to binary FDA risk (e.g., 5–10% of a biotech allocation depending on risk tolerance).
Value remains in the FDA decision and US launch while the SERB deal has strengthened the cash position.
Sentiment has strengthened due to concrete progress toward the US market and validation of Idefirix in clinical practice.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 12 Nov 2026 — Report shows sharply higher revenue from SERB license deal and strengthened cash position, improving outlook ahead of FDA decision.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (9) — follow the company freeAbout the company
Hansa Biopharma is a biotech company developing and commercializing immunomodulating enzyme therapies. Its lead product Idefirix (imlifidase) enables desensitization ahead of kidney transplantation in highly sensitized patients, alongside a pipeline in autoimmune and transplant-related indications. The company is commercial/growth-stage but not yet profitable and is highly dependent on U.S. regulatory and commercial execution.
Bull case
Steps toward a Nasdaq listing broaden the institutional investor base and secure financing ahead of a potential US launch.
Bear case
The announced directed share issue and new depositary receipts entail imminent dilution risk.
Why this signal
Value remains in the FDA decision and US launch while the SERB deal has strengthened the cash position.
Recent news
The Q3 report was published on 11 November with revenue of 143 MSEK driven by SERB license income. Cash position reached 1 337 MSEK. Positive PAES data were presented at ASN Kidney Week and the IND application for HNSA-5487 was submitted. The share rose sharply to 44.76 SEK on the report day.